Learn About Homozygous Familial Hypercholesterolemia (HoFH)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Penn Heart And Vascular Center
Daniel Rader is a Cardiologist and a Medical Genetics provider in Philadelphia, Pennsylvania. Dr. Rader is rated as an Elite provider by MediFind in the treatment of Homozygous Familial Hypercholesterolemia (HoFH). His top areas of expertise are High Cholesterol, Homozygous Familial Hypercholesterolemia (HoFH), Coronary Heart Disease, Atherosclerosis, and Heart Transplant. Dr. Rader is currently accepting new patients.
Smidt Heart Institute
Prediman Shah is a Cardiologist in Los Angeles, California. Dr. Shah is rated as an Elite provider by MediFind in the treatment of Homozygous Familial Hypercholesterolemia (HoFH). His top areas of expertise are Atherosclerosis, Homozygous Familial Hypercholesterolemia (HoFH), Coronary Heart Disease, High Cholesterol, and Hormone Replacement Therapy (HRT).
Atrium Health Levine Children's HEARTest Yard Congenital Heart Center
Jacob Hartz is a Pediatrics specialist and a Pediatric Cardiologist in Charlotte, North Carolina. Dr. Hartz is rated as an Advanced provider by MediFind in the treatment of Homozygous Familial Hypercholesterolemia (HoFH). His top areas of expertise are Homozygous Familial Hypercholesterolemia (HoFH), Ventricular Septal Defects, Tetralogy of Fallot, Heart Murmurs, and Pacemaker Implantation. Dr. Hartz is currently accepting new patients.
Summary: This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 2 to \<12 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDLC).
Summary: This multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous familial hypercholesterolemia (HoFH). After completion of the double blind (DB) treatment period subjects will be eligible to continue in the optional open-label extension (OLE...